

4
RECEIVED
3/11/02
82W
MAR 06 2002

PATENT
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicants: M. R. Schrimpf et al.

Serial NO.: 09/833,914

Filed: April 12, 2001

Title: DIAZABICYCLIC CENTRAL
NERVOUS SYSTEM ACTIVE AGENTS

Case No.: 6696.US.02



Group Art No.: 1615

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to or being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Assistant Commissioner for Patents
Washington, D.C. 20231, on:

Date of Deposit: February 26, 2002

Tanya Parent 2/26/02
Tanya Parent Date

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed, to the knowledge of the undersigned, before the mailing date of a first Office Action on the merits. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.



ABBOTT LABORATORIES
Telephone: (847) 938-3490
Facsimile: (847) 938-2623

Respectfully submitted,
M. R. Schrimpf, et al.

Michael J. Ward
Registration No. 37,960
Attorney for Applicants

RECEIVED

MAR 06 2002

1615
TECHNICAL CENTER 1600/2900
PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: M. R. Schrimpf et al.

Serial No.: 09/833,914

Filed: April 12, 2001

Title: DIAZABICYCLIC
CENTRAL NERVOUS SYSTEM ACTIVE AGENTS

Case No.: 6696.US.02

Group Art No.: 1615

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to or being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Assistant Commissioner for Patents
Washington, D.C. 20231, on:

Date of Deposit: February 26, 2002

Tanya Parent 2/26/02
Tanya Parent Date

Commissioner for Patents
Washington D.C. 20231

TRANSMITTAL LETTER

Dear Sir:

Enclosed herewith for the patent application identified above entitled DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS are the following:

1. Information Disclosure Statement;
2. Form PTO 1449, in duplicate;
3. References as cited on PTO 1449 (54 references); and
4. Return Receipt Postcard.

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.



* 2 3 4 9 2 *

23492

ABBOTT LABORATORIES
Telephone: (847) 938-3490
Facsimile: (847) 938-2623

Respectfully submitted,
M. R. Schrimpf, et al.

Michael J. Ward
Michael J. Ward
Registration No. 37,960
Attorney for Applicants